IP Library Assignment 073302/0334
Patent Assignment
Reel/Frame 073302/0334

Security Interest

Recorded: 2025-12-23 Pages: 11
Assignors
COLLEGIUM PHARMACEUTICAL, INC.
Executed: 2025-12-23
Assignee
TRUIST BANK, A NORTH CAROLINA CHARTERED BANK
303 PEACHTREE STREET NE, ATLANTA, GEORGIA, 30308
Covered Properties (39)
Abuse resistant transmucosal drug delivery device
Patent: 9,522,188 →
Application: 11/639,408 →
Publication: US 2007/0148097
Transmucosal Delivery Devices with Enhanced Uptake
Patent: 8,147,866 →
Application: 13/184,306 →
Publication: US 2011/0262522
Methods and Compositions for Treatment of Attention Deficit Disorder
Patent: 9,028,868 →
Application: 13/429,292 →
Publication: US 2012/0276017
Abuse-Resistant Mucoadhesive Devices for Delivery of Buprenorphine
Patent: 8,703,177 →
Application: 13/590,094 →
Publication: US 2013/0045268
Transmucosal Drug Delivery Devices for Use in Chronic Pain Relief
Patent: 9,901,539 →
Application: 13/724,959 →
Publication: US 2014/0178440
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 8,927,010 →
Application: 14/230,053 →
Publication: US 2014/0212483
Methods for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 8,916,588 →
Application: 14/230,067 →
Publication: US 2014/0212461
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,119,809 →
Application: 14/255,529 →
Publication: US 2014/0227197
Methods for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,034,902 →
Application: 14/577,963 →
Publication: US 2015/0110868
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,023,389 →
Application: 14/589,839 →
Publication: US 2015/0125521
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,283,214 →
Application: 14/704,836 →
Publication: US 2015/0231125
Method of Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,603,808 →
Application: 14/710,453 →
Publication: US 2015/0238443
Methods of Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,603,809 →
Application: 14/716,777 →
Publication: US 2015/0313849
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,289,394 →
Application: 14/841,428 →
Publication: US 2015/0366816
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,498,447 →
Application: 15/069,734 →
Publication: US 2016/0193156
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,511,032 →
Application: 15/076,253 →
Publication: US 2016/0199312
Transmucosal Delivery Devices with Enhanced Uptake
Patent: 9,597,288 →
Application: 15/198,961 →
Publication: US 2016/0310409
Transmucosal Delivery Devices with Enhanced Uptake
Patent: 9,655,843 →
Application: 15/212,912 →
Publication: US 2016/0324768
Process of Making Stable Abuse-Deterrent Oral Formulations
Patent: 9,737,530 →
Application: 15/255,859 →
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 15/359,202 →
Publication: US 2017/0071864
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 15/366,900 →
Publication: US 2017/0079937
Methods of Treatment of Attention Deficit Hyperactivity Disorder
Application: 15/470,697 →
Publication: US 2017/0296477
Methods for Treatment of Attention Deficit Hyperactivity Disorder
Patent: 9,889,095 →
Application: 15/470,705 →
Publication: US 2017/0196817
Process of Making Stable Abuse-Deterrent Oral Formulations
Patent: 9,968,598 →
Application: 15/649,024 →
Publication: US 2017/0368057
Process of Making Stable Abuse-Deterrent Oral Formulations
Application: 15/950,656 →
Publication: US 2018/0289697
Process of Making Stable Abuse-Deterrent Oral Formulations
Application: 16/218,801 →
Publication: US 2019/0255038
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 16/227,932 →
Publication: US 2019/0125689
Tamper-Resistant Pharmaceutical Compositions of Opioids and Other Drugs
Application: 16/413,242 →
Publication: US 2019/0262335
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 16/802,700 →
Publication: US 2020/0197316
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 16/802,742 →
Publication: US 2020/0197317
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 17/108,710 →
Publication: US 2021/0077416
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 17/124,102 →
Publication: US 2021/0100750
Methylphenidate Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 17/316,252 →
Publication: US 2021/0267957
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 17/557,524 →
Publication: US 2022/0110878
Methylphenidate Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 18/057,819 →
Publication: US 2023/0120738
Abuse-Resistant Mucoadhesive Devices for Delivery of Buprenorphine
Application: 18/330,238 →
Publication: US 2024/0165102
Compositions for Treatment of Attention Deficit Hyperactivity Disorder
Application: 18/416,548 →
Publication: US 2024/0226023
Abuse-Resistant Mucoadhesive Devices for Delivery of Buprenorphine
Application: 18/788,070 →
Publication: US 2025/0064796
Process of Making Stable Abuse-Deterrent Oral Formulations
Application: 19/087,090 →
Publication: US 2025/0213554
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 29, 2012
From: ZHANG, FENG
To: FORMULATION TECHNOLOGIES, LLC, DBA PHARMAFORM
Reel/Frame 029424/0359 →
Assignment of Assignor's Interest Nov 29, 2012
From: FINN, ANDREW; VASISHT, NIRAJ
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 029375/0695 →
Corrective Assignment to Correct the Application Number Previously Recorded on Reel 029375 Frame 0695. Assignor(S) Hereby Confirms the Assignment. Nov 30, 2012
From: FINN, ANDREW; VASISHT, NIRAJ
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 029388/0845 →
Assignment of Assignor's Interest Jan 2, 2013
From: FINN, ANDREW; VASISHT, NIRAJ
To: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Reel/Frame 029553/0429 →
Security Agreement Jul 8, 2013
From: BIODELIVERY SCIENCES INTERNATIONAL, INC.; ARIUS TWO, INC.
To: MIDCAP FINANCIAL SBIC, LP
Reel/Frame 030763/0336 →
Master Development Agreement Oct 31, 2013
From: HIGHLAND THERAPEUTICS, INC.
To: PHARMAFORM
Reel/Frame 031609/0883 →
Assignment of Assignor's Interest Oct 31, 2013
From: LICKRISH, DAVID
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 031552/0812 →
Assignment of Assignor's Interest Nov 15, 2013
From: HIGHLAND THERAPEUTICS, INC.
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 031733/0639 →
Corrective Assignment to Correct Assignee/Assignor Names; Previously Recorded at Reel 031609 Frame 0883. Assignor(S) Hereby Confirms the Assignment. Feb 19, 2014
From: FORMULATION TECHNOLOGIES L.L.C. D/B/A PHARMAFORM
To: HIGHLAND THERAPEUTICS INC.
Reel/Frame 032425/0435 →
Assignment of Assignor's Interest Apr 3, 2014
From: ZHANG, FENG
To: FORMULATION TECHNOLOGIES, LLC, DBA PHARMAFORM
Reel/Frame 032611/0146 →
Assignment of Assignor's Interest Apr 3, 2014
From: LICKRISH, DAVID
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 032611/0128 →
Assignment of Assignor's Interest Apr 3, 2014
From: FORMULATION TECHNOLOGIES, L.L.C. D/B/A PHARR
To: HIGHLAND THERAPEUTICS INC.
Reel/Frame 032611/0130 →
Assignment of Assignor's Interest Apr 3, 2014
From: HIGHLAND THERAPEUTICS, INC.
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 032611/0124 →
Assignment of Assignor's Interest Apr 3, 2014
From: FORMULATION TECHNOLOGIES, L.L.C. D/B/A PHARR
To: HIGHLAND THERAPEUTICS INC.
Reel/Frame 032611/0137 →
Assignment of Assignor's Interest Apr 3, 2014
From: ZHANG, FENG
To: FORMULATION TECHNOLOGIES, LLC, DBA PHARMAFORM
Reel/Frame 032611/0144 →
Assignment of Assignor's Interest Apr 3, 2014
From: HIGHLAND THERAPEUTICS, INC.
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 032611/0122 →
Assignment of Assignor's Interest Apr 3, 2014
From: LICKRISH, DAVID
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 032611/0126 →
Assignment of Assignor's Interest Apr 25, 2014
From: ZHANG, FENG
To: FORMULATION TECHNOLOGIES, LLC, DBA PHARMAFORM
Reel/Frame 032799/0931 →
Assignment of Assignor's Interest Apr 25, 2014
From: LICKRISH, DAVID
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 032799/0978 →
Assignment of Assignor's Interest Apr 25, 2014
From: HIGHLAND THERAPEUTICS, INC.
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 032800/0028 →
Master Development Agreement May 8, 2014
From: FORMULATION TECHNOLOGIES L.L.C. D/B/A PHARMAFORM
To: HIGHLAND THERAPEUTICS INC.
Reel/Frame 032845/0794 →
Assignment of Assignor's Interest Jan 7, 2015
From: LICKRISH, DAVID
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 034741/0294 →
Assignment of Assignor's Interest Jan 7, 2015
From: FORMULATION TECHNOLOGIES LLC DBA PHARMAFORM
To: HIGHLAND THERAPEUTICS INC.
Reel/Frame 034729/0571 →
Assignment of Assignor's Interest Jan 7, 2015
From: HIGHLAND THERAPEUTICS, INC.
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 034654/0547 →
Assignment of Assignor's Interest Jan 7, 2015
From: HIGHLAND THERAPEUTICS, INC.
To: IRONSHORE PHARMACEUTICALS & DEVELOPMENT, INC.
Reel/Frame 034652/0787 →